Aardvark intends to enrol 90 patients across Australia, Canada, South Korea, the UK, and the US.

Dr. Lee added, “Enrollment in HERO is progressing steadily and remains on track to report topline data in the third quarter of 2026. We believe these data will further inform our understanding of ...

A Prescription Drug User Fee Act target date of December 27, 2024 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ. The company will ...

Family genetics evaluations. Several family visits with the geneticist and subsequent laboratory evaluations revealed that Bobby had PWS. It was also established that his siblings did not have the ...

Treatment with intranasal carbetocin was not associated with a statistically significant improvement in hyperphagia compared with placebo. Topline results were announced from a phase 3 trial ...

-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with ...

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients ...

New research from the University of East Anglia (UK) reveals the hidden struggles experienced by the brothers and sisters of people with Prader-Willi syndrome. Prader-Willi syndrome is a rare genetic ...

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint Acadia Pharmaceuticals Inc. (Nasdaq ...

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 ...

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ...